KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi.

• Main Authors: Regis Gomes (Author), Clarissa Teixeira (Author), Fabiano Oliveira (Author), Phillip G Lawyer (Author), Dia-Eldin Elnaiem (Author), Claudio Meneses (Author), Yasuyuki Goto (Author), Ajay Bhatia (Author), Randall F Howard (Author), Steven G Reed (Author), Jesus G Valenzuela (Author), Shaden Kamhawi (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2012-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Recombinant KSAC and L110f are promising Leishmania vaccine candidates. Both antigens formulated in stable emulsions (SE) with the natural TLR4 agonist MPL® and L110f with the synthetic TLR4 agonist GLA in SE protected BALB/c mice against L. major infection following needle challenge. Considering th...